

Amgen completed its acquisition of Immunex Corporation on July 15, 2002. This archived Immunex press releases is provided for reference only.

FOR IMMEDIATE RELEASE, August 13, 2001

Immunex, Wyeth-Ayerst Initiate RADIUS, One of The Largest Longitudinal Studies of Rheumatoid Arthritis Patients

Study to Provide Insight into Practice Patterns, Utilization and Tolerability Of Disease Modifying Anti Rheumatic Drugs (DMARDs) and Biologic Response Modifiers

SEATTLE - Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE: AHP), announced today that they will sponsor a 10,000-patient rheumatoid arthritis (RA) study. RADIUS (Rheumatoid Arthritis DMARD Intervention and Utilization Study) is designed to gain more comprehensive knowledge regarding current treatment for this chronic and debilitating disease.

"This study is designed to analyze 'real world' treatment experience of our patients with rheumatoid arthritis," said Allan Gibofsky, MD, JD, Professor of Medicine and Public Health at Weill Medical College of Cornell University and Attending Rheumatologist at The Hospital for Special Surgery in New York City. "Given the size of the database, the study should yield important clinical and safety information about our current treatment regimens."

The RADIUS trial is specifically designed to collect data on:

- RA treatment practice patterns;
- Tolerability of RA therapies; and
- Efficacy of current disease modifying anti-rheumatic drugs (DMARDs) and biologic response modifiers.

An independent advisory board comprised of academic and community-based rheumatologists has provided input into the design and implementation of the study. This board will also be involved in evaluating and interpreting data collected in RADIUS.

"There are relatively few databases and little reliable data that can provide a clear picture of how various therapies are used by community physicians in patients with RA," said George Spencer-Green, MD, MS, franchise medical director, Immunex Corporation. "This study is designed to provide a better understanding of such use."

RADIUS STUDY DESIGN

RADIUS is divided into two parts:

- RADIUS 1 is a study of 5,000 adult patients who meet the ACR criteria for RA diagnosis and currently require an introduction of a new DMARD to RA therapy. This DMARD can be a change from, or an addition to, current treatment regimen. This is a multi-center trial, and patients will be recruited by approximately 600 investigators nationwide. RADIUS 1 is scheduled to begin in the late summer of 2001 and data will be collected for at least two years.
- RADIUS 2 will study an additional 5,000 adult patients who will begin new treatment with ENBREL® (etanercept). These patients will meet the same criteria as for RADIUS 1. This will also be a multi-center trial and patients will be recruited by the same 600 investigators.

RADIUS 2 is targeted to begin in 2002 when additional supplies of ENBREL become available, and data will be collected for at least two years.

ABOUT ENBREL

An application for marketing approval of ENBREL was fast-tracked by the U.S. Food and Drug Administration in 1998. Six months after the application was submitted, the FDA approved ENBREL for reducing the signs and symptoms of moderately to severely active RA in patients who have had an inadequate response to one or more DMARDs. The following year, the FDA approved ENBREL for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to DMARDs. In June 2000, the FDA approved ENBREL for reducing signs and symptoms and inhibiting structural damage in patients with moderately to severely active RA. ENBREL is the only TNF inhibitor approved for use both with methotrexate or alone. It is also the only TNF inhibitor approved for use as a first-line therapy for RA.

ENBREL acts by binding TNF, one of the dominant cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that cause the inflammatory process of RA and psoriatic arthritis. ENBREL competitively inhibits binding of TNF molecules to the TNF receptor (TNFr) sites. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.

SINCE THE PRODUCT WAS FIRST INTRODUCED, SERIOUS INFECTIONS, SOME INVOLVING DEATH, HAVE BEEN REPORTED IN PATIENTS USING ENBREL. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS WHO WERE PRONE TO INFECTIONS, SUCH AS THOSE WITH ADVANCED OR POORLY CONTROLLED DIABETES. RARE CASES OF TUBERCULOSIS HAVE ALSO BEEN REPORTED. ENBREL SHOULD BE DISCONTINUED IN PATIENTS WITH SERIOUS INFECTIONS. DO NOT START ENBREL IF YOU HAVE AN INFECTION OF ANY TYPE OR IF YOU HAVE AN ALLERGY TO ENBREL OR ITS COMPONENTS. ENBREL SHOULD BE USED WITH CAUTION IN PATIENTS PRONE TO INFECTION. CONTACT YOUR PHYSICIAN IF YOU HAVE ANY QUESTIONS ABOUT ENBREL OR INFECTIONS.

There have been rare reports of serious nervous system disorders such as multiple sclerosis, seizures or inflammation of the nerves of the eyes. Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL. There have also been rare reports of serious blood disorders, some involving death. **Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness.** It is unclear if ENBREL has caused these nervous system or blood disorders. If your doctor confirms serious blood problems, you may need to stop using ENBREL.

The most frequent adverse events in placebo-controlled clinical trials involving 349 adults were injection site reactions (ISR) (37%), infections (35%), and headache (17%). Only the rate of ISR was higher than that of placebo. The most frequent adverse events in a methotrexate-controlled clinical trial of 415 adults with early-stage RA were infections (64%), ISR (34%), and headache (24%). Only the rate of ISR was higher than that of methotrexate. In all 1,197 RA patients studied, malignancies were rare (1%).

In a study of 69 patients with JRA, infections (62%), headache (19%), abdominal pain (19%), vomiting (13%), and nausea (9%) occurred more frequently than in adults. The types of infections reported in JRA patients were generally mild and consistent with those commonly seen in children. Serious adverse reactions reported rarely were chicken pox (3%), gastroenteritis (3%), serious infection (2%), depression/personality disorder (1%), skin ulcer (1%), inflammation in parts of the upper digestive tract (1%), and diabetes (1%).

Immunex Corporation and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP), market ENBREL in North America. Other AHP affiliates market ENBREL outside of

North America. Immunex manufactures ENBREL. Additional information about ENBREL, including full prescribing information, can be found on the company-sponsored Web site at (www.enbrel.com) or by calling toll-free 888-4ENBREL (888-436-2735). Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

Wyeth-Ayerst Laboratories, a division of American Home Products, is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular disease therapies, central nervous system drugs, anti-inflammatory gastrointestinal agents, vaccines, oncology and hemophilia products.

American Home Products Corporation is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It also is a global leader in vaccines, biotechnology and animal health care.

NOTE: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, our supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation and other risk factors listed from time to time in reports filed by Immunex with the SEC, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operations and Our Stock Price" within our most recently filed Form 10-Q. The forward-looking statements contained in this news release represent our judgment as of the date of this release. Immunex undertakes no obligation to publicly update any forward-looking statements.